Benzer Pharmacy Selected to Dispense Purixan®

Benzer Pharmacy has been approved to dispense Purixan® as a partner for limited distribution drugs based on the pharmacy’s expertise in clinical excellence. A product of Rare Disease Therapeutics, Inc., Purixan® is the first FDA-Approved oral suspension form of mercaptopurine. Purixan® offers flexibility and accuracy of dosing, consistent absorption and is a palatable alternative to... (Read more)
Trends in Specialty Pharmacy in the United States

Trends in Specialty Pharmacy

What are the trends in specialty pharmacy? What to expect in the following period? Let’s see some insightful information from the industry. Please follow... (Read more)
340B Program Drug Pricing

340B Program Drug Pricing

The 340B program emerged in the early nineties under the Bush administration to provide a pharmaceutical purchasing reductions for specific covered entities. In essence, pharmaceutical manufacturers were asked to provide discounted drug pricing to private, non-profit or government-owned institutions where high drug costs can be detrimental to the intended public service. More specifically, children’s hospitals,... (Read more)
Benzer Pharmacy Selected for a Limited Distribution Drug, Purixan®

Benzer Pharmacy Selected for Aralast™ Distribution

Patients with Hereditary Emphysema can seek Aralast™, a limited distribution drug from America’s fastest growing independent specialty pharmacy chain. Benzer Pharmacy is now a specialty provider for Aralast™, a limited distribution drug. Aralast™ is also known as Alpha 1 proteinase inhibitor (A1PI). The drug treats patients with hereditary emphysema. Aralast™ is made from human blood... (Read more)